Voyageur Pharmaceuticals Ltd (VM) - Total Assets

Latest as of November 2025: CA$3.11 Million CAD ≈ $2.25 Million USD

Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VM) holds total assets worth CA$3.11 Million CAD (≈ $2.25 Million USD) as of November 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VM cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Voyageur Pharmaceuticals Ltd - Total Assets Trend (2011–2025)

This chart illustrates how Voyageur Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See Voyageur Pharmaceuticals Ltd shareholders equity for net asset value and shareholders' equity analysis.

Voyageur Pharmaceuticals Ltd - Asset Composition Analysis

Current Asset Composition (November 2025)

Voyageur Pharmaceuticals Ltd's total assets of CA$3.11 Million consist of 19.2% current assets and 80.8% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 8.6%
Accounts Receivable CA$134.05K 4.3%
Inventory CA$49.17K 1.6%
Property, Plant & Equipment CA$0.00 0.0%
Intangible Assets CA$0.00 0.0%
Goodwill CA$0.00 0.0%

Asset Composition Trend (2011–2025)

This chart illustrates how Voyageur Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Voyageur Pharmaceuticals Ltd (VM) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Voyageur Pharmaceuticals Ltd's current assets represent 19.2% of total assets in 2025, a decrease from 100.0% in 2011.
  • Cash Position: Cash and equivalents constituted 8.6% of total assets in 2025, down from 76.1% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
  • Asset Diversification: The largest asset category is accounts receivable at 4.3% of total assets.

Voyageur Pharmaceuticals Ltd Competitors by Total Assets

Key competitors of Voyageur Pharmaceuticals Ltd based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Celltrion Pharm Inc
KQ:068760
Korea ₩745.80 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
China CN¥11.80 Billion
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
China CN¥3.12 Billion

Voyageur Pharmaceuticals Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.33 0.17 0.03
Quick Ratio 0.30 0.14 0.02
Cash Ratio 0.00 0.00 0.00
Working Capital CA$-1.22 Million CA$-1.74 Million CA$-884.80K

Voyageur Pharmaceuticals Ltd - Advanced Valuation Insights

This section examines the relationship between Voyageur Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 19.23
Latest Market Cap to Assets Ratio 5.41
Asset Growth Rate (YoY) 19.5%
Total Assets CA$3.11 Million
Market Capitalization $16.79 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Voyageur Pharmaceuticals Ltd's assets at a significant premium (5.41x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Voyageur Pharmaceuticals Ltd's assets grew by 19.5% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Voyageur Pharmaceuticals Ltd (2011–2025)

The table below shows the annual total assets of Voyageur Pharmaceuticals Ltd from 2011 to 2025.

Year Total Assets Change
2025-11-30 CA$3.11 Million
≈ $2.25 Million
+19.50%
2024-11-30 CA$2.60 Million
≈ $1.88 Million
+20.09%
2023-11-30 CA$2.16 Million
≈ $1.57 Million
+3.26%
2022-11-30 CA$2.10 Million
≈ $1.52 Million
-18.37%
2021-11-30 CA$2.57 Million
≈ $1.86 Million
+101.29%
2020-11-30 CA$1.28 Million
≈ $922.45K
-20.64%
2019-11-30 CA$1.61 Million
≈ $1.16 Million
+26.87%
2018-11-30 CA$1.27 Million
≈ $916.14K
+45.59%
2017-11-30 CA$869.88K
≈ $629.26K
+22.64%
2016-11-30 CA$709.32K
≈ $513.11K
+693.81%
2015-11-30 CA$89.36K
≈ $64.64K
-44.15%
2014-11-30 CA$160.00K
≈ $115.75K
-13.32%
2013-11-30 CA$184.60K
≈ $133.53K
-24.60%
2012-11-30 CA$244.82K
≈ $177.10K
+18.72%
2011-11-30 CA$206.21K
≈ $149.17K
--

About Voyageur Pharmaceuticals Ltd

V:VM Canada Drug Manufacturers - Specialty & Generic
Market Cap
$16.79 Million
CA$23.22 Million CAD
Market Cap Rank
#25602 Global
#1004 in Canada
Share Price
CA$0.13
Change (1 day)
+0.00%
52-Week Range
CA$0.08 - CA$0.20
All Time High
CA$0.34
About

Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more